Northern Light Cardiology Research conducts research in collaboration with several national research groups including TIMI Study Group at Brigham and Women’s Hospital in Boston, Massachusetts; The Harvard Clinical Research Institute (now known as Baim Clinical Research Institute) also in Boston; New England Research Institute; and Duke Clinical Research Institute.
The research team is headed by Alan Wiseman, MD, FACC, FSCAI, and is supported by his associates at Northern Light Cardiology. The team is made up of eight members, including a Supervisor/RN, lead research nurse, four nurse coordinators, a medical assistant, an office/regulatory coordinator and a secretary/research assistant. Each member brings invaluable expertise to their roles in conducting cardiology research.
Dr. Wiseman and his team assess each patient for eligibility for participation in a trial. Cardiac patients who are potentially eligible must meet specific requirements depending on the trial.
Some current clinical research trials conducted at Northern Light Cardiology are focusing on coronary stents, electrophysiology, devices, novel medications to treat coronary disease, hyperlipidemia, obesity, congestive heart failure, and more. For a complete list of trials, visit our Current Trials page, and for more details on each trial, visit clinicaltrials.gov.
Contact Northern Light Cardiology Research at 207-275-3860 with any questions.
Return to Northern Light Cardiology
Current Cardiology Research Trials (Updated November 2018)
ABSORB III RCT: a prospective randomized, single-blind, multi-center trial. It is the pivotal trial to support the US pre-market approval (PMA) of Absorb™ Bioresorbable Vascular Scaffold (BVS). ABSORB IV: the continuation of ABSORB III and the data from ABSORB III and ABSORB IV will be pooled to support the ABSORB IV primary endpoint. Both the trials will evaluate the safety and effectiveness of Absorb BVS.
AEGIS II: A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL 112 in subjects with acute coronary syndrome.
BIONICS: Study of BioNIR Drug Eluting Stent System in Coronary Stenosis.
CHAMP HF: Observational registry of treatment patterns in US HF pts with reduced EF.
DalGenE: A Phase III, Double-blind, Randomized Placebo-controlled Study to Evaluate the Effects of Dalcetrapib on Cardiovascular (CV) Risk in a Genetically Defined Population with a Recent Acute Coronary Syndrome (ACS).
FOURIER OLE: A Multicenter, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of Evolocumab.
Galactic-HF: A double-blind, randomized, placebo-controlled multicenter study to assess the efficacy & safety of Omecamtive Mecarbil on mortality and morbidity in patients with CHF and reduced EF.
MPP-PMS: MultiPoint Pacing Post Market Study.
NAVIGATE X4: The objective of the NAVIGATE X4 Clinical Study is to gather data to establish the safety, performance and effectiveness of the ACUITY™ X4 quadripolar coronary venous leads and the RELIANCE 4-FRONT™ ventricular defibrillation leads to satisfy FDA requirements for pre-market submission. Additionally, data from this study will be used to support post-market approval requirements for the ACUITY X4 and RELIANCE 4-FRONT leads.
Paradise MI: A multicenter, randomized, double-blind, active-controlled, parallel group Phase 3 study to evaluate the efficacy and safety of LCZ696 compared to Ramipril on morbidity and mortality in high risk patients following an acute myocardial infarction.
Plexa: Prospective, single-arm, non-randomized, multi-center registry.
PROTEGO DF4 Post Approval Registry: The purpose of this registry study is to confirm the long-term safety and reliability of the Protego DF4 right ventricular lead.
QP ExCELs: The QP ExCELs study is designed to confirm safety and efficacy of the BIOTRONIK Sentus OTW QP left ventricular leads to satisfy FDA requirements for regulatory approval of the leads in the US. Long-term safety of the BIOTRONIK Sentus OTW QP left ventricular leads will be confirmed during a post approval phase.
Quadripolar: The purpose of this post approval study is to evaluate the acute and chronic performance of a Quadripolar CRT-D device system in a patient population indicated for cardiac resynchronization therapy.
Regeneron R1500-CL-1643: A randomized, double-blind, placebo-controlled study of the safety and efficacy of varying doses and dose regimens of Evinacumab in patients with persistent hypercholesterolemia despite maximally tolerated lipid modifying therapy.
Regeneron NeuroCog R727-CL-1532: Randomized, double-blind, placebo-controlled study to evaluate the effect of Praluent on Neurocognitive Function in patients with Heterozygous Familial Hypercholesterolemia or with Non-Familial Hypercholesterolemia at High and Very High Cardiovascular Risk.
Scored: A randomized, double-blind, placebo controlled, parallel group, multicenter study to demonstrate the effects of sotagliflozin on cardiovascular and renal events in patients with Type II Diabetes, cardiovascular risk factors and moderately impaired renal function.
THEMIS: The purpose of this study is to compare the effect of ticagrelor versus placebo in patients with Type 2 Diabetes Mellitus.
Xience 90: Xience short DAPT study.